Benitec Biopharma Inc. (BNTC) stock
BNTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.15−0.39 (-4.57%)
Close on Nov 17, 2026Market cap $284.29MP/E –Yield –
Benitec Biopharma cash
Cash and short-term investments held at the end of each period.
Benitec Biopharma's cash was $179.97M at Jun 30, 2026. For fiscal 2026 it was $179.97M, up 84.1% from the year before. The highest annual figure on record is $179.97M in fiscal 2026.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $179.97M | +84.1% |
| FY2025 | Jun 30, 2025 | $97.74M | +91.9% |
| FY2024 | Jun 30, 2024 | $50.93M | +1945.3% |
| FY2023 | Jun 30, 2023 | $2.49M | -38.9% |
| FY2022 | Jun 30, 2022 | $4.08M | -79.4% |
| FY2021 | Jun 30, 2021 | $19.78M | +101.5% |
| FY2020 | Jun 30, 2020 | $9.82M | -37.5% |
| FY2019 | Jun 30, 2019 | $15.72M | +32.3% |
| FY2018 | Jun 30, 2018 | $11.88M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $179.97M | +84.1% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $184.76M | +78.6% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $188.79M | +141.0% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $94.48M | +39.1% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $97.74M | +91.9% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $103.45M | +630.8% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $78.35M | +284.3% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $67.91M | +162.4% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $50.93M | +1945.3% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $14.16M | +115.6% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $20.39M | +93.2% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $25.88M | +56.4% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $2.49M | -38.9% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $6.57M | -23.9% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $10.55M | -14.5% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $16.55M | +5.1% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $4.08M | -79.4% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $8.63M | -28.0% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $12.34M | -11.9% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $15.74M | +111.3% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $19.78M | +101.5% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $11.99M | +5.2% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $14.01M | +1.6% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $7.45M | -55.2% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $9.82M | -37.5% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $11.40M | -4.0% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $13.79M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $16.63M | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $15.72M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $11.88M | – |
See a number that looks wrong?